Press

Featured In

BusinessWire
April 29, 2024

First Patient Dosed with NILK-2301 in Phase I Clinical Trial

Featured In

BusinessWire
April 15, 2024

NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression